Unmet needs, uncommon commitment: The shift toward investment in rare diseases

January 19, 2017 Erin Righetti

Join biotech leaders, emerging innovators, investors and patient advocacy group representatives for a candid, interactive and enlightening panel discussion about the evolving landscape in rare disease drug discovery and development. The panel discuss how approaches to rare disease research, drug development, commercialization and investment have changed in recent years, and why and how they’ve chosen to pursue leadership and innovation in rare diseases.


Moderator: Alison Silva – Critical Outcome Technologies

  • Debra Miller – CureDuchenne
  • Henri Termeer – Formerly Genzyme; Aura Biosciences
  • Phil Vickers – Shire
  • Flemming Ornskov – Shire

About the Author

Erin Righetti

Editor-in-Chief, Insight

Follow on Twitter More Content by Erin Righetti
Previous Article
Fireside Chat with Bryan Roberts

Gain insights from one of the industry’s most successful investors, featured on the Forbes Midas list eight...

Next Article
What’s ahead with the new Trump administration?

The life sciences industry has had some challenging moments with lawmakers in recent years. So, how will th...